Lotus Pharmaceuticals Announces New Patent for Diabetes Drug

Lotus Pharmaceuticals, Inc. (LTUS) announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.